M Checkpoint 2 Cell Cycle Arrest at the G Enzyme Activity Enhances Sensitivity to Doxorubicin-induced Expression of CD 26 and Its Associated Dipeptidyl Peptidase IV Updated

CD26, a Mr 110,000 surface-bound ectopeptidase with dipeptidyl peptidase IV (DPPIV) activity, has an array of diverse functional properties, with a role in T-cell physiology and the development of certain human cancers. In this study, we report that surface expression of CD26, through its associated DPPIV enzyme activity, enhanced sensitivity of Jurkat T-cell transfectants to G2-M arrest induced by the chemotherapeutic drug, doxorubicin. This was associated with disruption of cell cycle-related events, including hyperphosphorylation and inhibition of p34 kinase activity, phosphorylation of cdc25C, and alteration in cyclin B1 expression. In addition, we demonstrate that the addition of exogenous soluble DPPIV enhanced sensitivity of lymphoid tumor cell lines to doxorubicin, suggesting a potentially useful clinical role for CD26/DPPIV in the treatment of selected human hematological malignancies.

[1]  G. Mills,et al.  In vitro and in vivo antitumor effect of the anti-CD26 monoclonal antibody 1F7 on human CD30+ anaplastic large cell T-cell lymphoma Karpas 299. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[2]  N. Dang,et al.  Absence of CD26 expression is a useful marker for diagnosis of T-cell lymphoma in peripheral blood. , 2001, American journal of clinical pathology.

[3]  Roland Martin,et al.  Targeting Dipeptidyl Peptidase IV (CD26) Suppresses Autoimmune Encephalomyelitis and Up-Regulates TGF-β1 Secretion In Vivo1 , 2001, The Journal of Immunology.

[4]  S. Iwata,et al.  Internalization of CD26 by mannose 6-phosphate/insulin-like growth factor II receptor contributes to T cell activation. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[5]  R. Poon,et al.  G1 versus G2 cell cycle arrest after adriamycin‐induced damage in mouse Swiss3T3 cells , 1999, FEBS letters.

[6]  J. Decaprio,et al.  Cytoplasmic Localization of Human cdc25C during Interphase Requires an Intact 14-3-3 Binding Site , 1999, Molecular and Cellular Biology.

[7]  E. Bosmans,et al.  Constitutive expression of CD26/dipeptidylpeptidase IV on peripheral blood B lymphocytes of patients with B chronic lymphocytic leukaemia , 1999, British Journal of Cancer.

[8]  Dominique Schols,et al.  Amino-terminal Truncation of Chemokines by CD26/Dipeptidyl-peptidase IV , 1998, The Journal of Biological Chemistry.

[9]  Chika Morimoto,et al.  The structure and function of CD26 in the T‐cell immune response , 1998, Immunological reviews.

[10]  B. Fleischer,et al.  Dipeptidyl‐peptidase IV/CD26 on T cells: analysis of an alternative T‐cell activation pathway , 1998, Immunological reviews.

[11]  M. Hegen,et al.  Determination of adenosine deaminase binding domain on CD26 and its immunoregulatory effect on T cell activation. , 1997, Journal of immunology.

[12]  M. Ditto,et al.  Regulation of the Receptor Specificity and Function of the Chemokine RANTES (Regulated on Activation, Normal T Cell Expressed and Secreted) by Dipeptidyl Peptidase IV (CD26)-mediated Cleavage , 1997, The Journal of experimental medicine.

[13]  T. Hunter,et al.  The role of Cdc2 feedback loop control in the DNA damage checkpoint in mammalian cells. , 1997, Cancer research.

[14]  C. Peng,et al.  Mitotic and G2 checkpoint control: regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216. , 1997, Science.

[15]  L. Bolondi,et al.  Aberrant dipeptidyl peptidase IV (DPP IV/CD26) expression in human hepatocellular carcinoma. , 1997, Journal of hepatology.

[16]  J. Kupiec-Weglinski,et al.  Inhibition of CD26/dipeptidyl peptidase IV activity in vivo prolongs cardiac allograft survival in rat recipients. , 1997, Transplantation.

[17]  M. Hegen,et al.  Cross‐linking of CD26 by antibody induces tyrosine phosphorylation and activation of mitogen‐activated protein kinase , 1997, Immunology.

[18]  S. Kornbluth,et al.  Regulatory roles of cyclin dependent kinase phosphorylation in cell cycle control. , 1996, Current opinion in cell biology.

[19]  R. Perez-soler,et al.  Cell cycle-dependent cytotoxicity, G2/M phase arrest, and disruption of p34cdc2/cyclin B1 activity induced by doxorubicin in synchronized P388 cells. , 1996, Molecular pharmacology.

[20]  M. Hegen,et al.  Characterization of adenosine deaminase binding to human CD26 on T cells and its biologic role in immune response. , 1996, Journal of immunology.

[21]  S. Monfardini,et al.  The expression of CD26 and CD40 ligand is mutually exclusive in human T-cell non-Hodgkin's lymphomas/leukemias. , 1995, Blood.

[22]  K. Umeki,et al.  CD26 (dipeptidyl peptidase IV/DPP IV) as a novel molecular marker for differentiated thyroid carcinoma , 1995, International journal of cancer.

[23]  M. Kirschner,et al.  Mitosis in transition , 1994, Cell.

[24]  W. Dunphy,et al.  The decision to enter mitosis. , 1994, Trends in cell biology.

[25]  C. Morimoto,et al.  Enhancement of antigen-induced T-cell proliferation by soluble CD26/dipeptidyl peptidase IV. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[26]  C. Morimoto,et al.  Direct association of adenosine deaminase with a T cell activation antigen, CD26. , 1993, Science.

[27]  C. Morimoto,et al.  The costimulatory activity of the CD26 antigen requires dipeptidyl peptidase IV enzymatic activity. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[28]  S. Vijayasaradhi,et al.  A marker for neoplastic progression of human melanocytes is a cell surface ectopeptidase , 1993, The Journal of experimental medicine.

[29]  C. Morimoto,et al.  Biochemical characterization of CD26 (dipeptidyl peptidase IV): functional comparison of distinct epitopes recognized by various anti-CD26 monoclonal antibodies. , 1992, Molecular immunology.

[30]  C. Morimoto,et al.  1F7 (CD26): a marker of thymic maturation involved in the differential regulation of the CD3 and CD2 pathways of human thymocyte activation. , 1991, Journal of immunology.

[31]  C. Morimoto,et al.  Coassociation of CD26 (dipeptidyl peptidase IV) with CD45 on the surface of human T lymphocytes. , 1991, Journal of immunology.

[32]  B. Huber,et al.  Inhibition of dipeptidyl aminopeptidase IV (DP-IV) by Xaa-boroPro dipeptides and use of these inhibitors to examine the role of DP-IV in T-cell function. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[33]  C. Morimoto,et al.  Cell surface modulation of CD26 by anti-1F7 monoclonal antibody. Analysis of surface expression and human T cell activation. , 1990, Journal of immunology.

[34]  C. Morimoto,et al.  Human CD4 helper T cell activation: functional involvement of two distinct collagen receptors, 1F7 and VLA integrin family , 1990, The Journal of experimental medicine.

[35]  C. Morimoto,et al.  Comitogenic effect of solid-phase immobilized anti-1F7 on human CD4 T cell activation via CD3 and CD2 pathways. , 1990, Journal of immunology.

[36]  N. Letvin,et al.  1F7, a novel cell surface molecule, involved in helper function of CD4 cells. , 1989, Journal of immunology.

[37]  M. Hansen,et al.  Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. , 1989, Journal of immunological methods.

[38]  G. Mills,et al.  In Vitro and in Vivo Antitumor Effect of the Anti-CD 26 Monoclonal Antibody 1 F 7 on Human CD 30 1 Anaplastic Large Cell T-Cell Lymphoma Karpas 2991 , 2001 .

[39]  I. Hoffmann,et al.  Cell cycle regulation by the Cdc25 phosphatase family. , 2000, Progress in cell cycle research.

[40]  D. Hafler,et al.  FcR-mediated crosslinking of Ta1 (CDw26) induces human T lymphocyte activation. , 1990, Cellular immunology.